Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedtrastuzumab deruxtecan
Educational only, not medical advice. OncoForge makes no claim that Trastuzumab Deruxtecan treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Reported figures
What supports this page
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Guideline
0
Meta-analysis
0
Systematic review
0
Randomized trial
0
Clinical trial
1
Observational
0
Case report
0
Review
0
Preclinical
0
Other
0
1 studies1 human
Tracking 1 published study of Trastuzumab Deruxtecan: 1 in humans.
Reported direction across studies: 1 positive.
These counts summarize what the studies reported; they are not a measure of whether Trastuzumab Deruxtecan works.
This phase II study tested trastuzumab deruxtecan in people with recurrent uterine carcinosarcoma whose tumors expressed HER2. The study found tumor responses in both the HER2-high and HER2-low groups, and the median progression-free survival and overall survival were reported for each group. Side effects were common, including some serious adverse events and pneumonitis/interstitial lung disease, but the authors said they were generally manageable with monitoring.
Reported effects: ORR by central review 54.5% [32.2–75.6], n=22 · ORR by central review 70% [34.8–93.3], n=10 · +6 more
Key findings
Central-review ORR was 54.5% in the HER2-high group and 70.0% in the HER2-low group.
Investigator-assessed ORR was 68.2% in the HER2-high group and 60.0% in the HER2-low group.
Median PFS was 6.2 months in the HER2-high group and 6.7 months in the HER2-low group.
Median OS was 13.3 months in the HER2-high group and not reached in the HER2-low group.
Grade ≥3 adverse events occurred in 61% of patients.
Pneumonitis/interstitial lung disease occurred in 24% at grade 1-2 and 3% at grade 3.
Limitations: Single-arm study with no control group; Small sample size; Short/unclear follow-up for survival outcomes; Subgroup analyses were exploratory; Safety and efficacy were assessed in a selected HER2-expressing recurrent population.
This study evaluated an anticancer agent in patients with HER2-expressing uterine carcinosarcoma.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Trastuzumab Deruxtecan's evidence base, and anything that's been retracted.
Cancers where Trastuzumab Deruxtecan reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Limitations: Single-arm study with no control group; Small sample size; Short/unclear follow-up for survival outcomes; Subgroup analyses were exploratory; Safety and efficacy were assessed in a selected HER2-expressing recurrent population.
Evidence at a glance: Trastuzumab Deruxtecan by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
These are doses as studied or reported, never a recommendation. The right amount of Trastuzumab Deruxtecan depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.